Research programme: leucine rich repeat kinase 2 tageting oligonucleotides - Korro Bio
Alternative Names: Research programme: LRRK2 protein tageting oligonucleotides - Korro BioLatest Information Update: 31 Mar 2025
At a glance
- Originator Korro Bio
- Class Antiparkinsonians; Neuroprotectants; Oligonucleotides
- Mechanism of Action LRRK2 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Parkinson's disease
Most Recent Events
- 13 Mar 2025 Early research in Parkinson's disease in USA (Parenteral), before March 2025 (Korro Bio pipeline, March 2025)